Diplomat specialty pharmacy distributes Otezla for psoriatic arthritis
FLINT, Mich.— April 07, 2014 — Diplomat has announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Otezla® was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. Diplomat has access to dispense Otezla® immediately.
In clinical trials, Otezla® demonstrated the ability to reduce the signs and symptoms of psoriatic arthritis. Otezla® is the first oral therapy available for the treatment of psoriatic arthritis, a form of arthritis primarily affecting individuals who have been diagnosed with psoriasis. The primary signs and symptoms of psoriatic arthritis are joint pain, stiffness and swelling of the fingers and tendons. According to the National Psoriasis Foundation, approximately 30 percent of people with psoriasis will develop psoriatic arthritis.
Per manufacturer’s instructions, patients taking Otezla® should have their weight monitored regularly by a healthcare professional. If clinically significant or unexplained weight loss occurs while taking Otezla®, the patient should be evaluated and discontinuation of therapy should be considered. The most common side effects experienced by patients taking Otezla® were diarrhea, nausea and headache. In clinical trials, patients taking Otezla® were also associated with more reports of depression compared to those patients on placebo.
Otezla® is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation. Otezla has not been studied in pregnant women.
Otezla® is manufactured for Celgene Corporation. Full prescribing information for Otezla® is available at the manufacturer’s website.
About Celgene Corporation
Celgene Corporation is an integrated global pharmaceutical company headquartered in Summit, New Jersey, focused on the development of innovative therapies for the treatment of cancer and inflammatory diseases.
Media contacts: Abigail Bearman, Diplomat; 810.768.9563; email@example.com. Gary Rice, R.Ph., Diplomat; 810.768.9863; firstname.lastname@example.org.
@thehubflintRT @thehubflint: Part 2 of the Frontlines series is here! Read about Lindsay Baywol, @michiganstateu student & @DiplomatRx #Flint https://t…1 day ago
@DiplomatRxDiplomat Dispensing Opioid-Overdose Antidote Naloxone to Michigan Residents https://t.co/RjYzr2oCML1 day ago
@thehubflintRT @thehubflint: Learn how Gina Kim is “living in the moment’ while being a @DiplomatRx fellow in #Flint. @skypointflint @Georgetown https:…1 day ago
@DiplomatRxDiplomat is holding open interviews on August 17 at our headquarters in #Flint Michigan!6 days ago
@thehubflintRT @thehubflint: Gina Kim, @Georgetown student, shares her experience of being a 2017 @DiplomatRx Fellow in #Flint. @flintfwd https://t.co/…2 weeks ago